Please use this identifier to cite or link to this item: http://hdl.handle.net/11054/1736
Title: Prolonged viral shedding in patients with mild to moderate COVID-19 disease: A regional perspective .
Author: Hossain, Mehrab E.
Lister, David
Bartolo, Caroline
Kinsella, Paul
Knox, James
Aldrich, Rosemary
Cowan, Raquel
Commons, Robert J.
Issue Date: 2021
Publication Title: Infectious Diseases: Research and Treatment
Volume: 14
Start Page: 1
End Page: 3
Abstract: Background The risk of transmission of Coronavirus Disease 2019 (COVID-19) is increasingly understood to be greatest early after symptom onset, however, factors associated with prolonged and increased risk of transmission remain unclear. In settings where COVID-19 prevalence is low, there may be a benefit of extending the period that patients are isolated to decrease the risk of transmission. This study explored the duration of viral shedding in such a location, in patients with mild-moderate COVID-19 disease in Ballarat, Australia. Methods Patients diagnosed with COVID-19 disease using a real-time reverse-transcriptase–polymerase-chain-reaction (RT-PCR) assay from oropharyngeal and bilateral deep nasopharyngeal sampling and managed through Ballarat Health Services between March 1 and May 1, 2020 were included. Patients were retested if they were afebrile for >72 hours, asymptomatic and >14 days since symptom onset. If positive on retesting, patients were tested every 3 to 7 days thereafter. Results Patients underwent testing a median of 4 days (range 1-12) after initial symptom onset. Duration of symptoms ranged from 1 to 36 days. Positive tests were recorded up to a median of day 21 (range 6-38). Cycle thresholds were inversely correlated with time since symptom onset (P < .0001). Median time to the first negative test was 25 days (range 12-32). Two patients who had remained asymptomatic for >7 days after initial symptom onset had recrudescence of mild symptoms on day 13 and 14; both tested positive on follow-up tests at this time. Conclusions This study demonstrates prolonged shedding of COVID-19 in patients with mild-moderate disease. It suggests that some patients with mild disease may have recrudescence of symptoms a week or more after their initial symptoms resolved.
URI: http://hdl.handle.net/11054/1736
DOI: https://doi.org/10.1177/11786337211010428
Internal ID Number: 01702
Health Subject: COVID-19
SARS-CoV-2
SHEDDING
AUSTRALIA
MILD
Type: Journal Article
Article
Appears in Collections:Research Output

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.